Aurobindo Pharma updates on solar project, biologicals restructuring

Aurobindo Pharma announced that its acquisition of up to a 26% stake in Swarnaakshu Solar Power Private Limited, originally targeted for completion by September 30, 2025, will now be finalized by December 31, 2025. This delay is pending state government approval for setting up a captive solar power plant, which is crucial for the required investment in Swarnaakshu.

In a separate development, Aurobindo Pharma's step-down subsidiary, CuraTeQ Biologics B.V., incorporated a new wholly-owned subsidiary in Malta named CuraTeQ Biologics (Malta) Limited on September 26, 2025. This new entity, with an initial share capital of €1200, aims to expand the company's pharmaceutical products business in Malta.

Additionally, the transfer of shares of CuraTeQ Biologics s.r.o. from Helix Healthcare B.V. to CuraTeQ Biologics B.V., originally planned for August 31, 2025, is now expected to be completed by November 30, 2025. This postponement is due to pending receipt of an updated business register from authorities in The Netherlands reflecting the share transfer.